Oxybutynin Chloride
Product Images NDC 50090-4192

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 50090-4192). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500904192)

Oxybutynin Chloride Extended Release 5 mg tablets carton from A-S Medication Solutions, containing 90 extended-release tablets. The label includes storage instructions to keep the product at 77 degrees F protected from moisture and humidity and notes that each tablet contains 5 mg oxybutynin chloride in an extended-release formulation. Dosage instructions advise seeing the package insert.*

FDA Label Image

Chemical Structure (Oxybutynin Chloride Extended Release 1)

Chemical structure of oxybutynin chloride, the active ingredient in Oxybutynin Chloride Extended Release by A-S Medication Solutions (NDC 50090-4192). The structure shows bonds and functional groups typical for oxybutynin chloride including aromatic rings and an amine hydrochloride salt.*

FDA Label Image

Figure 1 (Oxybutynin Chloride Extended Release 2)

A line graph comparing mean plasma R-oxybutynin concentration (ng/mL) over 24 hours in two dosing regimens: oxybutynin chloride extended-release tablets 10 mg once daily (QD) and oxybutynin 5 mg three times daily (TID). The graph shows concentration changes over time with error bars indicating variability.*

FDA Label Image

Figure 2 (Oxybutynin Chloride Extended Release 3)

A line graph showing the mean plasma concentration of R-Oxybutynin over 24 hours. The x-axis represents time in hours (0 to 24), and the y-axis shows plasma concentration in ng/mL (0.0 to 2.0). Data points with error bars indicate fluctuation in concentration levels over time.*

FDA Label Image

Figure 3 (Oxybutynin Chloride Extended Release 4)

A chart depicting the mean change in episodes per week from baseline for Oxybutynin Chloride Extended Release tablets compared to placebo. The horizontal axis measures mean change with standard deviation, showing a negative change for the active drug and near zero for placebo, indicating reduction in episodes with Oxybutynin Chloride Extended Release tablets.*

FDA Label Image

Figure 4 (Oxybutynin Chloride Extended Release 5)

A horizontal bar chart comparing mean change in episodes per week from baseline between Oxybuynin chloride extended-release tablets and placebo. The chart includes error bars representing standard deviation for each group.*

FDA Label Image

Figure 5 (Oxybutynin Chloride Extended Release 6)

A horizontal bar chart showing the mean change with standard deviation in episodes per week from baseline for oxybutynin chloride extended-release tablets compared to oxybutynin. The chart plots values on a scale from -40 to +40 episodes per week, illustrating reductions in episodes for both treatments.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.